OBJECTIVE: To investigate whether 3 months' preoperative treatment with lanreotide improved outcome in newly diagnosed patients with acromegaly resulting from invasive pituitary macroadenoma. METHODS: After baseline evaluation, untreated patients were randomized to undergo direct trans-sphenoidal surgery or lanreotide treatment (30 mg via intramuscular injection every 2 weeks, increased to 30 mg/week at week 8 if growth hormone nadir > 2.5 μg/l), for 3 months prior to surgery. Tumour shrinkage following lanreotide treatment was analysed. Cure was evaluated at 3 months postsurgery by measuring growth hormone and insulinlike growth factor-1 (IGF-1) levels. RESULTS: Preoperative lanreotide treatment significantly reduced mean tumour size. Growth hormone and IGF-1 levels were lower in the pretreatment group than in the direct surgery group at 3 months postsurgery. According to combined growth hormone and IGF-1 levels, significantly more patients were cured by trans-sphenoidal surgery in the pretreatment group compared with the direct surgery group (11 of 24 and five of 25 patients, respectively). CONCLUSIONS: Lanreotide treatment for 3 months before trans-sphenoidal surgery effectively reduced tumour size, and improved surgical cure rate, in newly diagnosed patients with acromegaly resulting from invasive pituitary macroadenoma.
MeijBPLopesMSEllegalaDB: The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg2002; 96: 195–208.
2.
GongJZhaoYFattahR Abdel: Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas. Pituitary2008; 11: 37–48.
3.
LundinPPedersenF: Volume of pituitary macroadenomas: assessment by MRI. J Comput Assist Tomogr1992; 16: 519–528.
DalyAFRixhonMAdamC: High prevalence of pituitary adenomas: A cross-sectional study in the province of Liège, Belgium. J Clin Endocrinol Metab2006; 91: 4769–4775.
6.
BuchfelderM: Management of aggressive pituitary adenomas: current treatment strategies. Pituitary2009; 12: 256–260.
7.
MelmedS: Medical progress: acromegaly. N Engl J Med2006; 355: 2558–2573.
8.
NomikosPBuchfelderMFahlbuschR: The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur J Endocrinol2005; 152: 379–387.
9.
ShouXFLiSQWangYF: Treatment of pituitary adenomas with a transsphenoidal approach. Neurosurgery2005; 56: 249–256.
MelmedSSternbergRCookD: A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab2005; 90: 4405–4410.
12.
MaizaJCVezzosiDMattaM: Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf)2007; 67: 282–289.
13.
VanceMLLawsERJr: Role of medical therapy in the management of acromegaly. Neurosurgery2005; 56: 877–885.
14.
TurnerHEThornton-JonesVAWassJA: Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clin Endocrinol (Oxf)2004; 61: 224–231.
15.
ShenMShouXWangY: Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: A prospective randomized study. Endocr J2010; 57: 1035–1044.
16.
ColaoAPivonelloRMarzulloP: Severe systemic complications of acromegaly. J Endocrinol Invest2005; 28: 65–77.
17.
VieiraJOJrCukiertALibermanB: Evaluation of magnetic resonance imaging criteria for cavernous sinus invasion in patients with pituitary adenomas: logistic regression analysis and correlation with surgical findings. Surg Neurol2006; 65: 130–135.
18.
CookDMEzzatSKatznelsonL: AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly. Endocr Pract2004; 10: 213–225.
19.
KnospESteinerEKitzK: Pituitary adenomas with invasion of the cavernous sinus space: A magnetic resonance imaging classification compared with surgical findings. Neurosurgery1993; 33: 610–618.
20.
LissettCAPeaceySRLaingI: The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clin Endocrinol (Oxf)1998; 49: 653–657.
21.
ShimonICohenZRRamZ: Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery2001; 48: 1239–1245.
22.
BeckersA: Does preoperative somatostatin analog treatment improve surgical cure rates in acromegaly? A new look at an old question. J Clin Endocrinol Metab2008; 93: 2975–2977.
23.
SheppardMC: Primary medical therapy for acromegaly. Clin Endocrinol (Oxf)2003; 58: 387–399.
24.
ThaparKKovacsKScheithauerBW: Diagnosis and management of pituitary tumors. In: Pituitary Surgery (ThaparKEdwardR eds). Totowa, NJ: Humana Press, 2001; pp 239.
25.
AbeTLüdeckeDK: Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol2001; 145: 137–145.
26.
BevanJS: Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab2005; 90: 1856–1863.
27.
KaravitakiNTurnerHEAdamsCB: Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol (Oxf)2008; 68: 970–975.
28.
MaoZGZhuYHTangHL: Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: A prospective, randomised trial. Eur J Endocrinol2010; 162: 661–666.
29.
CometsEMentréFGrassP: Population pharmacodynamic analysis of octreotide in acromegalic patients. Clin Pharmacol Ther2003; 73: 95–106.
30.
AstrucBMarbachPBouterfaH: Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol2005; 45: 836–844.
31.
LorcyYDejagerSChansonP: Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly. Pituitary2000; 3: 193–197.
32.
BexMAbsRSjoenGT: AcroBel—the Belgian registry on acromegaly: A survey of the ‘real-life’ outcome in 418 acromegalic subjects. Eur J Endocrinol2007; 157: 399–409.
33.
TrainerPJ: Editorial: acromegaly—consensus, what consensus?J Clin Endocrinol Metab2002; 87: 3534–3536.
34.
CarlsenSMLund-JohansenMSchreinerT: Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: A prospective, randomized trial. J Clin Endocrinol Metab2008; 93: 2984–2990.
